Abstract
Purpose: In animal models RSR13, a synthetic allosteric modifier of hemoglobin (I-Ib), oxygenates and thus radiosensitizes hypoxic solid tumors by decreasing the oxygen (Or) affinity of Hb. A phase Ib open label, multi-center dose-frequency escalation study was conducted to evaluate the safety, tolerance, pharmacokinetics, and pharmacodynamics of repeated daily intravenous (IV) infusions of RSRl3 administered to cancer patients receiving palliative radiation therapy (RT).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
